LeMaitre Vascular Q2 sales climb 10% as gross margin reaches 72.1%; FDA re-inspection concludes
LMAT sits 30% above its 52-week low of $79.395.
Summary
LeMaitre Vascular posted Q2 2026 net sales of $70.4 million (+10% YoY) and EPS of $0.74, with gross margin improving to 72.1%. The FDA completed a re-inspection of its Artegraft facility, identifying new observations.
Key Events · Earnings and Guidance · LMAT
-
Q2 Sales +10%, EPS $0.74
Net sales reached $70.4 million, a 10% increase year-over-year, with diluted EPS of $0.74, up 23% from $0.60 in Q2 2025.
-
Gross Margin Expands to 72.1%
Gross margin improved 210 basis points to 72.1%, driven by price increases, favorable product mix, and lower shipping costs.
-
FDA Re-Inspection Completed
The FDA completed a re-inspection of the Artegraft facility in June 2026 and identified new inspectional observations. The company continues to address the August 2025 warning letter.
-
$100M Buyback Authorized, Unused
The board authorized a $100 million share repurchase program in February 2026, but no shares have been repurchased to date.
Analysis · LMAT · Industrial Applications And Services
A solid quarter for LeMaitre Vascular saw sales rise 10% to $70.4 million and net income advance 24% to $17.1 million. Gross margin expanded 210 basis points to 72.1%, helped by price increases and a favorable product mix. The balance sheet remains robust, with $376 million in cash and securities against $169 million in convertible notes. An FDA re-inspection of the Artegraft facility wrapped up in June 2026, though new observations were noted — a regulatory overhang that warrants monitoring. The board also authorized a $100 million share buyback, but no repurchases have been made yet.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LMAT was trading at $103.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $79.40 to $118.01. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.